Comparative Pharmacology
Head-to-head clinical analysis: HYDROCODONE versus WESTADONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCODONE versus WESTADONE.
HYDROCODONE vs WESTADONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocodone is a semi-synthetic opioid agonist that binds to mu-opioid receptors in the central nervous system, inhibiting ascending pain pathways and altering perception of pain.
Mu-opioid receptor agonist; also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake.
5-10 mg orally every 4-6 hours as needed for pain; maximum 60 mg/day
Oral: 2.5-10 mg every 4-6 hours as needed for pain; maximum 40 mg per day.
None Documented
None Documented
Terminal elimination half-life is approximately 3.8-4.5 hours in adults; may be prolonged in hepatic or renal impairment.
Clinical Note
moderateHydrocodone + Torasemide
"The risk or severity of adverse effects can be increased when Hydrocodone is combined with Torasemide."
Clinical Note
moderateHydrocodone + Etacrynic acid
"The risk or severity of adverse effects can be increased when Hydrocodone is combined with Etacrynic acid."
Clinical Note
moderateHydrocodone + Furosemide
"The risk or severity of adverse effects can be increased when Hydrocodone is combined with Furosemide."
Clinical Note
moderateHydrocodone + Bumetanide
Terminal elimination half-life: 15-60 hours (mean ~24 hours). Clinical context: Prolonged half-life supports once-daily dosing in opioid maintenance; accumulation occurs with repeated dosing due to long half-life.
Renal (67%) as conjugated morphine and normorphine, norhydrocodone, and hydromorphone; fecal (negligible).
Primarily renal (40-50% as unchanged methadone and its metabolites, 15-20% as metadone-N-oxide), biliary/fecal (5-10%).
Category D/X
Category C
Opioid Agonist
Opioid Agonist
"The risk or severity of adverse effects can be increased when Hydrocodone is combined with Bumetanide."